Methods for determining the risk of a systemic lupus erythematosus (SLE) patient to develop neuropsychiatric syndromes
a systemic lupus erythematosus and risk factor technology, applied in the field of neuropsychiatric syndrome risk factors, can solve the problems of difficult diagnosis of neuropsychiatric sle (npsle) and poor quality of life of npsle patients, and achieve the effect of successfully distinguishing
Patent Information
- Authority / Receiving Office
- US · United States
- Patent Type
- Applications(United States)
- Current Assignee / Owner
- Publication Date
- 2018-08-16
- Estimated Expiration
- Not applicable · inactive patent
Abstract
Description
FIELD OF THE INVENTION
[0001] The present invention relates to methods for diagnosing neuropsychiatric syndromes concurrent with SLE. The present invention further relates to methods for determining whether an SLE patient is at risk of developing neuropsychiatric syndromes.BACKGROUND OF THE INVENTION
[0002] Systemic lupus erythematosus (SLE) is a chronic, recurrent, potentially fatal multisystem inflammatory disorder mainly affecting women. SLE is associated with a large spectrum of autoantibodies. IgG antibodies to more than 100 different antigens including DNA, nucleosomes, histones, viral antigens, transcription factors and more have been reported in different SLE patients (Sherer et al., 2004, Semin. Arthritis. Rheum. 34:501-37).
[0003] Peripheral neurologic syndromes and central nervous system (CNS) manifestations are recognized as primary disease manifestations in SLE. Neuropsychiatric SLE (NPSLE) involves a wide range of nervous system disorders, and can affect 50% or more of SLE p...
Examples
example 1
[0159]Unique Antigen-Autoantibody Reactivity Patterns Capable of Differentiating NPSLE Patients from Non-NPSLE Control Group
[0160]Materials and Methods
[0161]Human Subjects
[0162]The study was approved by the Institutional Review Board of the participating clinical unit; informed consent was obtained from all participants. All patient identifiers were kept confidential.
[0163]Thirty-eight SLE serum samples were obtained from the Einstein Lupus Cohort at the Albert Einstein College of Medicine (Bronx, N.Y.) and tested using the ImmunArray iCHIP, printed with a set of 225 antigens associated with SLE and / or brain injury. All SLE samples satisfied the ACR classification criteria. Twelve of the 38 patients were diagnosed as positive for NPSLE based on the use of a validated questionnaire.
[0164]Antigen Microarrays and Serum Testing
[0165]Antigen microarray chips were prepared as previously described (Quintana et al. Lupus. 2006; 15: 428-30). Briefly, the antigens were spotted on epoxy-activa...